Pfizer's acquisition of Seagen, which is the largest biopharma deal since 2019, comes as products received in previous deals begin…
McAlinden Research PartnersMarch 14, 2023
Expectations for AI in healthcare, particularly biopharma and diagnostics, have been high for several years now. New partnerships and acquisitions may…
McAlinden Research PartnersJanuary 17, 2023
The biopharma industry is kicking off the year with price hikes and some early signs of a sustained uptick in…
McAlinden Research PartnersJanuary 5, 2023
Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…
McAlinden Research PartnersOctober 19, 2022
The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…
McAlinden Research PartnersSeptember 29, 2022
M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…
McAlinden Research PartnersAugust 9, 2022
Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…
McAlinden Research PartnersJuly 14, 2022
A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…
McAlinden Research PartnersJuly 11, 2022
Throughout the past few months, MRP has highlighted significant cash balances among many biopharmaceutical giants. Though hundreds of billions of dollars…
McAlinden Research PartnersJune 14, 2022
